Adolescents HCV Geno 1 or 4 -.Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With/Without Ribavirin

In Case You Missed It
Hepatol Commun. 2018 Nov; 2(11): 1311–1319.
Published online 2018 Oct 5. doi: [10.1002/hep4.1250]

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4.
Daniel H. Leung, 1 Stefan Wirth, 2 Betty B. Yao, 3 Rolando M. Viani, 3 , 13 Regino P. Gonzalez‐Peralta, 4 , 14 Maureen M. Jonas, 5 Steven J. Lobritto, 6 Michael R. Narkewicz, 7 Etienne Sokal, 8 Clàudia Fortuny, 9 Evelyn K. Hsu, 10 Antonio Del Valle‐Segarra, 11 Jiuhong Zha, 3 Lois Larsen, 3 Li Liu, 3 Diana L. Shuster, 3 , 15 Daniel E. Cohen, 3 and Philip Rosenthal 1

Abstract

In adults, treatment of hepatitis C virus (HCV) infection with ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) with or without dasabuvir (DSV) and ±ribavirin (RBV) results in high rates of sustained virologic response (SVR). However, these regimens have not been investigated in adolescents. This ongoing, open‐label, phase 2/3 study evaluated the pharmacokinetics, safety, and efficacy of OBV/PTV/r+DSV±RBV treatment for 12 weeks in adolescents infected with HCV genotype (GT) 1 without cirrhosis (part 1) and the safety and efficacy of OBV/PTV/r±DSV±RBV treatment for 12 or 24 weeks in adolescents infected with GT1 or GT4 without cirrhosis or with compensated cirrhosis (parts 1 and 2). Patients were 12‐17 years of age and treatment naive or interferon experienced. Treatment regimens were based on HCV GT and cirrhosis status. Endpoints were SVR at posttreatment week 12 (SVR12), adverse events (AEs), and pharmacokinetic parameters. Thirty‐eight adolescents were enrolled, 66% were female patients, and 76% were White; 42%, 40%, and 18% of patients had HCV GT1a, GT1b, and GT4 infections, respectively. Median age was 15 years (range, 12‐17 years), and 1 patient had cirrhosis. The SVR12 rate was 100% (38/38; 95% confidence interval [CI], 90.8%‐100%). No treatment‐emergent grade 3 or 4 laboratory abnormalities were reported. No serious AEs occurred on treatment, and no AEs led to study drug discontinuation. The most common AEs were headache (21%), fatigue (18%), nasopharyngitis (13%), pruritus (13%), and upper respiratory tract infection (11%). Intensive pharmacokinetic results showed OBV, PTV, DSV, and ritonavir drug exposures were comparable to those seen in adults. Conclusion: Treatment with OBV/PTV/r±DSV±RBV was well tolerated and highly efficacious in adolescents with HCV GT1 or GT4 infection.

Full-text open access: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211326/